Communications and Marketing
Head of Communications and Marketing
Ulrike Grönefeld
Im Neuenheimer Feld 28069120 Heidelberg
Phone: +49 6221 422854
E-Mail: u.groenefeld@dkfz.de
Press Officer
Dr. Sibylle Kohlstädt
Im Neuenheimer Feld 28069120 Heidelberg
Phone: +49 6221 422843
E-Mail: s.kohlstaedt@dkfz.de
Recent Press Releases
Vaccination as a therapy: Experimental vaccine against cervical cancer successfully tested in mice
Computer-generated simulation of a HPV
© DKFZ
Scientists from the German Cancer Research Center (DKFZ) have developed an experimental vaccine to fight cervical cancer caused by human papillomaviruses (HPV). This has already been accomplished successfully in mice. Tumors regressed in half of the vaccinated animals. The scientists' goal is to develop a therapeutic vaccine for people who are already suffering from cancer or cancer precursors and, thus, no longer benefit from preventive vaccination.
“Life Time” – European research for a healthier future
© Spencer Phillips, EMBL-EBI
Our body's cells are constantly changing. But which of these changes are healthy developments and which lead to serious diseases? This is what LifeTime, a new transnational and interdisciplinary initiative of leading European researchers, aims to discover. The consortium is jointly coordinated by the Max Delbrück Center in Berlin and the Institut Curie in Paris, with the Helmholtz Association and the CNRS. Scientists from the DKFZ are also involved in the consortium. Life Time has now cleared an important hurdle: The consortium will be given one million euros and one year to develop a plan to embed its vision for a healthier future within the European research and innovation landscape.
New vaccine strategy against Epstein Barr virus
Epstein Barr viruses in blood vessels
© Adobe Stock/DKFZ
The Epstein Barr viruses (EBV) are very common and in most cases, an infection causes no harm. However, sometimes the outcome is a serious disease. There is no effective immunization protection against EBV so far, because the pathogen is very difficult to get hold of. Scientists from the German Cancer Research Center (DKFZ) in Heidelberg have now developed a new strategy for developing a vaccine against EBV that will simultaneously prepare the immune system for different stages of the pathogen. In this way, the researchers are convinced to have made major progress towards developing a vaccine against EBV.
